1.Small bowel obstruction after abdominoperineal resection for rectal cancer.
Kyu Hak SHIM ; Chul MOON ; Hee YOO
Journal of the Korean Society of Coloproctology 1992;8(2):129-135
No abstract available.
Rectal Neoplasms*
2.Total Fibulectomy for the Short Below Knee Stumps
Jae Ik SHIM ; Dong Eun KIM ; In Whan CHUNG ; Seong Kyu PARK ; Young Jong CHOI ; Hak Seung LEE
The Journal of the Korean Orthopaedic Association 1984;19(5):955-962
Although it is evident that even a very short below knee stump is superior to the lengest above knee stump, short below knee stumps present difficult pmblems in fitting prostheses. To solve these problems, twenty-nine short below knee amputees, those could not be fitted prostheses because of stump complications, had been treated by fibulectomy and resection of the peroneal nerve from March 1978 to March 1983. All the cases were followed up average 2 years and 3 months and the following results were obtained: 1. The complications of short below knee stumps decreased significantly after fibulectomy and res ection of the peroneal nerve. 2. After fibulectomy, weight bearing areas under the lateral tibial condyle increased considerably. 3. In group of below knee stumps between 5cm and 7.4cm long, P.T.B. prostheses with metal joints and thigh corsets should be fitted without difficulties. 4. In group of short below knee stumps between 7.5cm and 9.9cm long, P.T.B. prostheses with steel joints and thigh corsets, P.T.B. prostheses with knee cuff only, or supracondylar P.T.B. prostheses (K. B. M.) could be fitted selectively without any difficulty. 5. In group of short below knee stumps between 10cm and 12cm long, P. T.B. prostheses with knee cuff only or supracondylar P. T.B. prostheses could be fitted selectively without any difficulty. 6. After fibulectomy and resection of the peroneal nerve, all the short below knee amputees except for one case of very short stump (4.5cm long) could walk with their prostheses satisfactorily.
Amputees
;
Humans
;
Joints
;
Knee
;
Peroneal Nerve
;
Prostheses and Implants
;
Steel
;
Thigh
;
Weight-Bearing
3.Serum procollagen III aminopeptide levels in patients with kidney disease.
Han Sun CHO ; Sung Kyu HA ; Ho Yung LEE ; Dae Suk HAN ; Kyung Won LEE ; Kyung Whoon CHOI ; Young Hak SHIM
Korean Journal of Nephrology 1993;12(1):54-61
No abstract available.
Humans
;
Kidney Diseases*
;
Kidney*
;
Procollagen*
4.Clinical Analysis of Brain Scans Using Technetium-99M.
Sung Bo SHIM ; Jae Hak SHIN ; Yong Moon JUN ; Dae Jo KIM ; Yung Chul OK ; Kyu Woong LEE
Journal of Korean Neurosurgical Society 1976;5(2):69-74
Technetium 99 M pertechnetate has become a valuable for the radioisotopic brain scan. This was introduced by Haper in 1963 and is now widely used in the medical field. The advantages are easy administration, high count rate with potential for high speed scanning, absence of beta radiation and decreasing time for test. We used Siemens Scintimat 2 Scanner with a 3x2 inch Na(T1) crystal and 151-hole collimator in our study. 10 mci Technetium 99 M was injected intravenously and obtained both lateral, anterior and posterior view in 80 cases of brain lesion from Mar. 75 to Sep. 76. The scans were classified as positive, negative and suspicious. The overall detection rate in 40 cases of brain tumors was 60%, especially high uptake in mengioma, malignant pituitary tumor, astrocytoma, metastatic brain tumor and acoustic neuroma. But in nontumors diseases of the brain including CVA, head injury and hydrocephalus the uptake rate was a little value.
Astrocytoma
;
Beta Particles
;
Brain Neoplasms
;
Brain*
;
Craniocerebral Trauma
;
Hydrocephalus
;
Neuroma, Acoustic
;
Pituitary Neoplasms
;
Sodium Pertechnetate Tc 99m
;
Technetium
5.Surgical Treatment of Lipomyelomeningocele.
Sang Iel SHIM ; Sung Hak KIM ; Dong Been PARK ; Kyu Man SHIN
Journal of Korean Neurosurgical Society 1991;20(6):442-446
From January 1987 to December 1989, Six patients with lipomyelomeningocele were operated. There were 4 females and 2 males. The chief complaints that caused these patients to seek help were cosmetic effect of the mass on back, urinary incontinence, ankle deformity and weak leg. The postoperative results were as follows : Patient treated before developing neurological deficit remained unchanged neurologically. Patient treated after developing neurological deficitwere left with neurological sequelae. lipomyelomeningoceles are serious lesion which recommand early prohylactic surgery.
Ankle
;
Congenital Abnormalities
;
Female
;
Humans
;
Leg
;
Male
;
Urinary Incontinence
6.In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin.
Tae Hoon KIM ; Young Pil YUN ; Kyu Sik SHIM ; Hak Jun KIM ; Sung Eun KIM ; Kyeongsoon PARK ; Hae Ryong SONG
Tissue Engineering and Regenerative Medicine 2018;15(3):263-274
The aim of this study was to prepare inclusion nanocomplexes of hyaluronic acid-β-cyclodextrin and simvastatin (HA-β-CD/SIM) and evaluate in vitro anti-inflammation effects on lipopolysaccharide (LPS)-activated synoviocytes and chondrogenic differentiation effects on rat adipose-derived stem cells (rADSCs). The β-CD moieties in HA-β-CD could incorporate SIM to form HA-β-CD/SIM nanocomplexes with diameters of 297–350 nm. HA-β-CD/SIM resulted in long-term release of SIM from the nanocomplexes for up to 63 days in a sustained manner. In vitro studies revealed that HA-β-CD/SIM nanocomplexes were able to effectively and dose-dependently suppress the mRNA expression levels of proinflammatory markers such as matrix metallopeptidase-3 (MMP-3), MMP-13, cyclooxygenase-2 (COX-2), a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5), interleukin-6 (IL-6), and tumor necrosis factor (TNF-α) in LPS-stimulated synoviocytes. HA-β-CD/SIM-treated rADSCs significantly and dose-dependently enhanced mRNA expressions of aggrecan, collagen type II (COL2A1), and collagen type X (COL10A1), implying that HA-β-CD/SIM greatly induced the chondrogenic differentiation of rADSCs. Conclusively, HA-β-CD/SIM nanocomplexes will be a promising therapeutic material to alleviate inflammation as well as promote chondrogenesis.
Aggrecans
;
Animals
;
Chondrogenesis
;
Collagen Type II
;
Collagen Type X
;
Cyclooxygenase 2
;
In Vitro Techniques*
;
Inflammation
;
Interleukin-6
;
Rats
;
RNA, Messenger
;
Simvastatin*
;
Stem Cells
;
Thrombospondins
;
Tumor Necrosis Factor-alpha
7.A Case of Invasive Pulmonary Aspergillosis with Direct Invasion of the Mediastinum and the Left Atrium in an Immunocompetent Patient.
Kyu Hyun HAN ; Jung Hyun KIM ; Sun Young SHIN ; Hye Yun JEONG ; Ji Min CHU ; Hak Su KIM ; Daejin KIM ; Minjung SHIM ; Sang Ho CHO ; Eun Kyung KIM
Tuberculosis and Respiratory Diseases 2014;77(1):28-33
We report a case of invasive pulmonary aspergillosis invading the mediastinum and the left atrium. A 70-year-old woman was hospitalized for dyspnea. She had been well controlled for her diabetes mellitus and hypertension. The chest X-ray disclosed mediastinal widening, and the computed tomography scan of the chest showed that there was a large mediastinal mass and this lesion extended into the left atrium and right bronchus. The cardiac echocardiography showed that a huge mediastinal cystic mass compressed in the right atrium and a hyperechoic polypoid lesion in the left. The pathology from the bronchoscopic biopsy observed abundant fungal hyphae which was stained with periodic acid-Schiff and Gomori's methenamine silver. Despite the treatment with antifungal agents, she died from cardiac tamponade after three months. Invasive pulmonary aspergillosis, which involves the mediastinum and the heart, is very rare in immunocompetent patients.
Aged
;
Antifungal Agents
;
Biopsy
;
Bronchi
;
Cardiac Tamponade
;
Diabetes Mellitus
;
Dyspnea
;
Echocardiography
;
Female
;
Heart
;
Heart Atria*
;
Heart Neoplasms
;
Humans
;
Hypertension
;
Hyphae
;
Immunocompetence
;
Invasive Pulmonary Aspergillosis*
;
Mediastinal Cyst
;
Mediastinal Neoplasms
;
Mediastinum*
;
Methenamine
;
Pathology
;
Thorax
8.A Case of Invasive Pulmonary Aspergillosis with Direct Invasion of the Mediastinum and the Left Atrium in an Immunocompetent Patient.
Kyu Hyun HAN ; Jung Hyun KIM ; Sun Young SHIN ; Hye Yun JEONG ; Ji Min CHU ; Hak Su KIM ; Daejin KIM ; Minjung SHIM ; Sang Ho CHO ; Eun Kyung KIM
Tuberculosis and Respiratory Diseases 2014;77(1):28-33
We report a case of invasive pulmonary aspergillosis invading the mediastinum and the left atrium. A 70-year-old woman was hospitalized for dyspnea. She had been well controlled for her diabetes mellitus and hypertension. The chest X-ray disclosed mediastinal widening, and the computed tomography scan of the chest showed that there was a large mediastinal mass and this lesion extended into the left atrium and right bronchus. The cardiac echocardiography showed that a huge mediastinal cystic mass compressed in the right atrium and a hyperechoic polypoid lesion in the left. The pathology from the bronchoscopic biopsy observed abundant fungal hyphae which was stained with periodic acid-Schiff and Gomori's methenamine silver. Despite the treatment with antifungal agents, she died from cardiac tamponade after three months. Invasive pulmonary aspergillosis, which involves the mediastinum and the heart, is very rare in immunocompetent patients.
Aged
;
Antifungal Agents
;
Biopsy
;
Bronchi
;
Cardiac Tamponade
;
Diabetes Mellitus
;
Dyspnea
;
Echocardiography
;
Female
;
Heart
;
Heart Atria*
;
Heart Neoplasms
;
Humans
;
Hypertension
;
Hyphae
;
Immunocompetence
;
Invasive Pulmonary Aspergillosis*
;
Mediastinal Cyst
;
Mediastinal Neoplasms
;
Mediastinum*
;
Methenamine
;
Pathology
;
Thorax
9.Functional Dyspepsia and Subgroups in Korea and Short Term Outcome of Therapeutic Trial of Cisapride: Multicenter Study.
Chung HUH ; Chang Heon YANG ; Jae Guen JANG ; Dong Ho LEE ; Kook Lae LEE ; Sang Young SEOL ; Youn Jae LEE ; Sok Won HAN ; Kyu Sung RIM ; Poong Lyul RHEE ; Won Chang SHIN ; Kwang Jae LEE ; Moon Kwan CHUNG ; Yong Ho NAH ; Jun Myeong KIM ; Do Young KIM ; Sun Young LEE ; Pum Soo KIM ; Don Haeng LEE ; Yong Woon SHIN ; Kye Sook KWON ; Jong Sun REW ; Hyun Chul PARK ; Hwoon Yong JUNG ; Young Il MIN ; Sang In LEE ; Myung Gyu CHOI ; Kyu Wan CHOI ; Na Young KIM ; Seon Hee LIM ; Kye Heui LEE ; Sung Kook KIM ; Yong Hwan CHOI ; Chi Wook SONG ; Heu Rang KIM ; Chang Young YIM ; Jyung Dong BAE ; Pil Joong KANG ; Byung Min AHN ; Soo Heon PARK ; Hyun Yong JEONG ; Sei Jin YOUN ; Hyang Soon YEO ; Jeong Seop MOON ; Hyo Jin PARK ; Hak Yang KIM ; Sang Woo LEE ; Yong Chan LEE ; Moon Ho LEE ; Seong Ho CHOI ; Mi Hye JUNG ; Chan Sup SHIM ; Joon Seong LEE ; Young Woo KANG ; Jong Chul RHEE
Korean Journal of Gastrointestinal Motility 1998;4(1):1-12
BACKGROUND/AIMS: The aims of this study were to determine subgoups of functional dyspesia and to evaluate the short-term effect of cisapride in patients with functional dyspepsia in Korea. METHODS: 1025 patients, with a mean age of 42.6 years, with symptoms of functional dyspepsia, were recruited consecutively and upper gastrointestinal symptoms were investigated by interview in 41 hospitals in Korea. In an open, multicenter trial, 1025 patients received Smg of cisapride three times a day (TID) for at least .2 weeks for the treatment of symptoms of functional dyspepsia. When necessary, the dose of cisapride was increased to 10mg TID and the duration of therapy was extended to 4 weeks. RESULTS: The most frequently reported symptoms of functional dyspepsia were epigastric discomfort or fullness (85%), bloating (70%), belching (53%), early satiety (52%) and epigastric pain (46%) retrospectively. Subgroups of functional dyspepsia were as follows; dysmotility-like 73.5%, ulcer-like 39.7%, reflux-like 13.0%, and unspecified dyspepsia 14.0%. However, 33.2% of subjects with functional dyspepsia could be classified into more than one subgroup. Upper gastrointestinal symptoms were decreased to average 50.3% (range; 42.2 to 59.2%) after 2 weeks of cisapride treatment and to 25% (19.2 to 29.9%) after 4 weeks. cisapride therapy resulted in good or excellent improvement in 59.0% of the patients after two weeks, in 75% of patients after 4 weeks. Adverse events were occurred in 52 patients (5.8% of all patients), most commonly, loose stools or diarrhea (3.5%), abdominal pain (1.1%), and dizziness (0.3%). The majority of adverse events was mild and transient in nature and led to premature discontinuation of treatment in 4 patients. CONCLUSIONS: Although the majorities of patients with functional dyspepsia have dysmotility like symptoms in Korea, there is such overlap among the dyspepsia subgroups. Most patients responded well to a short therapeutic trial with cisapride without significant side effects.
Abdominal Pain
;
Cisapride*
;
Diarrhea
;
Dizziness
;
Dyspepsia*
;
Eructation
;
Humans
;
Korea*
;
Retrospective Studies
10.A Comparison of Tiotropium 18microgram, Once Daily and Ipratropium 40microgram, 4 Times Daily in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults with Chronic Obstructive Pulmonary Disease.
Seung Joon KIM ; Myung Sook KIM ; Sang Haak LEE ; Young Kyoon KIM ; Hwa Sik MOON ; Sung Hak PARK ; Sang Yeub LEE ; Kwang Ho IN ; Chang Youl LEE ; Young Sam KIM ; Hyung Jung KIM ; Chul Min AHN ; Sung Kyu KIM ; Kyung Rok KIM ; Seung Ick CHA ; Tae Hoon JUNG ; Mi Ok KIM ; Sung Soo PARK ; Cheon Woong CHOI ; Jee Hong YOO ; Hong Mo KANG ; Won Jung KOH ; Hyoung Suk HAM ; Eun Hae KANG ; O Jung KWON ; Yang Deok LEE ; Heung Bum LEE ; Yong Chul LEE ; Yang Keun RHEE ; Won Hyuk SHIN ; Sung Yeon KWON ; Woo Jin KIM ; Chul Gyu YOO ; Young Whan KIM ; Young Soo SHIM ; Sung Koo HAN ; Hye Kyung PARK ; Yun Seong KIM ; Min Ki LEE ; Soon Kew PARK ; Mi Hye KIM ; Won Yeon LEE ; Suk Joong YONG ; Kye Chul SHIN ; Byoung Whui CHOI ; Yeon Mok OH ; Chae Man LIM ; Sang Do LEE ; Woo Sung KIM ; Dong Soon KIM ; Sung Soo JUNG ; Ju Ock KIM ; Young Chun KO ; Young Chul KIM ; Nam Soo YOO
Tuberculosis and Respiratory Diseases 2005;58(5):498-506
BACKGROUND: This study compared the bronchodilator efficacy and safety of tiotropium inhalation capsules (18microgram once daily) with a ipratropium metered dose inhaler (2 puffs of 20microgram q.i.d.) in patients with chronic obstructive pulmonary disease (COPD). METHOD: After the initial screening assessment and a two-week run-in period, patients received either tiotropium 18microgram once daily or ipratropium 40microgram four times daily over a period of 4 weeks in a double blind, double dummy, parallel group study. The outcome measures were the lung function, the daily records of the peak expiratory flow rate (PEFR), the patients' questionnaire, and the use of concomitant salbutamol. The forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) were measured 5 minutes before inhalation, and 0.5, 1, 2 and 3 hours after inhaling the study drug on days 0, 14 and 28. RESULT: In 16 centers, 134 patients with a mean (SD) age of 66 (7) years and a predicted FEV1 of 42 (12)% were analyzed. The trough FEV1 response was significantly higher in the tiotropium group than in the ipratropium group after a four-week treatment period. The weekly mean morning PEFR of the tiotropium group was consistently higher than that of the ipratropium group during the 4-week treatment period with differences ranging from 12.52 to 13.88 l/min, which were statistically significant. Tiotropium was well tolerated by the COPD patients during the 4-week treatment period and had a similar safety profile to ipratropium. CONCLUSION: This study shows that tiotropium administrated once daily has a superior bronchodilator effect with a similar safety profile in treating COPD patients compared with ipratropium, inhaled four times daily.
Adult*
;
Albuterol
;
Bronchodilator Agents
;
Capsules
;
Forced Expiratory Volume
;
Humans
;
Inhalation
;
Ipratropium*
;
Lung
;
Mass Screening
;
Metered Dose Inhalers
;
Outcome Assessment (Health Care)
;
Peak Expiratory Flow Rate
;
Pulmonary Disease, Chronic Obstructive*
;
Surveys and Questionnaires
;
Vital Capacity
;
Tiotropium Bromide